Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Verastem, Inc.NASDAQ: VSTM
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $38.22M rose 31.1% year over year, behind the +33.3% change in trailing-twelve-month research & development. Sequentially, it rose 20.7% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.
Context
- Research & development amounted to 370.7% of revenue in FY2025, down 442.6 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +31.1% toward the trailing-twelve-month pace of +33.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 114.6M USD
- Year-over-year change
- +40.9%
- 4-year CAGR
- +30.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 114.6M | +40.9% |
| FY2024 | 2024-12-31 | 81.33M | +32.6% |
| FY2023 | 2023-12-31 | 61.36M | +21.4% |
| FY2022 | 2022-12-31 | 50.56M | +28.5% |
| FY2021 | 2021-12-31 | 39.35M | — |
Research & Development vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 research & development of $123.67M is the 4th highest of the 11 companies compared; the peer median is $91.94M.
- Its year-over-year change of +33.3% is the 3rd highest of 10, against a peer median of -9.4%.
- Research & development amounts to 249.4% of revenue for VSTM, versus a peer median of 382.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $140.37M | +74.2% | — | — |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $101.77M | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Jun 2024 | $56.93M | — | -15.5% | 877.1% | |
| LTM Mar 2026 | $31.62M | -19.6% | +9.2% | 6022.3% | |
| Peer median (excluding VSTM) | $91.94M | -9.4% | +5.1% | 382.5% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| Weighted Avg Shares | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
| Weighted Avg Shares (Diluted) | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.